Conceptual basis and methodology of the SOPHIA study

Pharmacogenomics

Volumn 8, Issue 11, 2007, Pages 1497-1509

  Glorioso, N ^a   Argiolas, G ^a   Filigheddu, F ^a   Troffa, C ^a   Cocco, F ^a   Bulla, E ^a   Bulla, P ^a   Zaninello, R ^a   Degortes, S ^a   Pitzoi, S ^a   Frau, F ^a   Fadda, S ^a   Parpaglia, P Pinna ^b   Bernini, G ^c   Bardini, M ^c   Fallo, F ^d   Malatino, L ^e   Regolisti, G ^f   Ferri, C ^g   Cusi, D ^h   Sciacqua, A ⁱ   Perticone, F ⁱ   Degli Esposti, E ^j   Baraccani, C ^j   Parati, G ^k   Veglio, F ^l   Mulatero, P ^l   Williams, T A ^l   Macciardi, F ^h   Stancanelli, B ^e   more..

^a UNIVERSITY OF SASSARI   (Italy)

^b SS Annunziata Hospital   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f S MARIA NUOVA HOSPITAL   (Italy)

^g UNIVERSITY OF L'AQUILA   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^j Ravenna Hospital   (Italy)

^k UNIVERSITY OF MILANO BICOCCA   (Italy)

^l UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

Drug therapy; Gene polymorphisms; High blood pressure; Pharmacogenomics; Renin angiotensin system; Whole genome scan

Indexed keywords

ALDOSTERONE; AMLODIPINE; BRAIN NATRIURETIC PEPTIDE; DRUG METABOLITE; HYDROCHLOROTHIAZIDE; LITHIUM; LOSARTAN;

ADRENERGIC SYSTEM; ADULT; AMBULATORY MONITORING; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL RESEARCH; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG METABOLISM; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; GENETIC ANALYSIS; HEART VOLUME; HOMEOSTASIS; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MICROALBUMINURIA; MONOTHERAPY; PHARMACOGENOMICS; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT TOLERANCE;

ADOLESCENT; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RESEARCH DESIGN;

EID: 37349107241     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.11.1497     Document Type: Article

References (83)

1. Carey RM, Siragy HM: Newly recognized components of the renin angiotensin system: potential roles in cardiovascular and renal regulation. Endocr. Rev. 24, 261-271 (2003).
2. Parfrey PS, Markandu ND, Roulston JE, Jones BE, Jones JC, MacGregor GA: Relation between arterial pressure, dietary sodium intake, and renin system in essential hypertension. Br. Med. J. (Clin Res Ed) 283, 94-97 (1981).
3. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T: International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52(3), 415-472 (2000).
4. Levy BI: How to explain the differences between renin angiotensin system modulators. Am. J Hypertens. 18(Suppl. 9 Pt 2), 134S-141S (2005).
5. Hall JE, Guyton A: Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin-angiotensin system. In: Hypertension, Pathophysiology, Diagnosis and Management. (Vol.1). Laragh JH, Brenner BM, (Ed.). Raven Press, NY, USA 1105-1129 (1990).
6. Staessen JA, Wang JG, Brand E et al.: Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J. Hypertens. 19, 1349-1358 (2001).
7. Wang J, Staessen JA, Tizzoni L et al.: Renal function in relation to three candidate genes. Am. J. Kidney Dis. 38(6), 1158-1168 (2001).
8. Sciarrone MS, Stella P, Barlassina C et al.: ACE and α-adducin polymorphism as markers of individual response to diuretic theraphy. Hypertension 41, 398-403 (2003).
9. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an agiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145-153 (2000).
10. Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273(18), 1450-1456 (1995).
11. Lonn EM, Yusuf S, Jha P et al.: Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90(4), 2056-2069 (1994).
12. Hansson L, Lindholm LH, Niskanen L et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project [CAPPP] randomised trial. Lancet 353, 611-616 (1999).
13. Estacic RO, Jeffers Bw, Batt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin independ diabetes and hypertension. N. Engl. J. Med. 338, 645-652 (1998).
14. Lindholm LH, Ibsen H, Dahlof B et al. for the LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 1004-1010 (2002).
15. Lithell H, Hansson L, Skogg I et al. for the SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind Intervention trial. J. Hypertens. 21, 875-886 (2003).
16. Schrader J, Kulschewski A, Dendorfer A: Inhibition of the renin-angiotensin system and the prevention of stroke. Am. J. Cardiovasc. Drugs 7 (1), 25-37 (2007).
17. Thomas MC, Atkins RC: Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs 66 (17), 2213-2234 (2006).
18. Pitt B, Poole-Wilson PA, Segal R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355, 1582-1587 (2000).
19. Cohn JN, Tognoni G for the Valsartan Heart Failure Trial investigators: a randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675 (2001).
20. Vogel F: Moderne probleme der humangenetik. Ergeb. Inn. Med. Kinderheilkd 12, 52-125 (1959).
21. Bianchi G, Staessen JA, Ferrari P: Pharmacogenomics of primary hypertension - the lessons from the past to look toward the future. Pharmacogenomics 3, 279-296 (2003).
22. Glorioso N, Manunta P, Filigheddu F et al.: The role of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 34, 649-654 (1999).
23. Glorioso N, Filigheddu F, Cusi D et al.: α-adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives. Hypertension 39, 357-362 (2002).
24. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E: C825T polymorphism of the G protein β(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 37, 739-743 (2001).
25. Fligheddu F, Reid JE, Troffa C et al.: Genetic polymorphisms of the β-adrenergic system: association with essential hypertension and response to β-blockade. Pharmacogenomics J. 4, 154-160 (2004).
26. Jia H, Hingorani AD, Sharma P et al.: Association of the G(s)α gene with essential hypertension and response to β-blockade. Hypertension 34(1), 8-14 (1999).
27. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ: Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J. Hypertens. 13(12 Pt 2), 1602-1609 (1995).
28. Stavroulakis GA, Makris TK, Krespi PG et al.: Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc. Drugs Ther. 14(4), 427-432 (2000).
29. Sookoian S, Castano G, Garcia SI, Viudez P, Gonzalez C, Pirola CJ: A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension. Am. J. Gastroenterol. 100(3), 636-642 (2005).
30. Lajer M, Tarnow L, Andersen S, Parving HH: CYP2C9 variant modifies blood pressure-lowering response to losartan in Type 1 diabetic patients with nephropathy. Diabet. Med. 24(3), 323-325 (2007).
31. Ortlepp JR, Hanrath P, Mevissen V, Kiel G, Borggrefe M, Hoffmann R: Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur. J. Pharmacol. 445(1-2), 151-152 (2002).
32. Kurland L, Melhus HA, Karlsson J et al.: Aldosterone synthase (CYP1132) - 344 C/T polymorphism is related to antihypertensive response: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am. J Hypertens.. 15, 389-393 (2002).
33. Kurland L, Melhus H, Karlsson J et al.: Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. J Hypertens. 19, 1783-1787 (2001).
34. Yasar U, Tybring G, Hidestrand M et al.: Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab. Dispos. 29(7), 1051-1056 (2001).
35. Babaoglu MO, Yasar U, Sandberg M et al.: CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur. J. Clin. Pharmacol. 60(5), 337-342 (2004).
36. Chobanian AV, Bakris GL, Black HR et al.: The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 289, 2560-2572 (2003).
37. Cifkova R, Erdine S, Fagard R et al.: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21(6), 1011-1053 (2003).
38. Law MR, Wald NJ, Morris JK, Jordan RE: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326(7404), 1427 (2003).
39. O'Brien E, Petrie J, Littler WA et al.: The British Hypertension Society protocol for the evaluation of blood pressure measuring devices. J. Hypertens. 11 (Suppl. 2), S43-S63 (1993).
40. Pickering TG, Shimbo D, Haas D: Ambulatory blood-pressure monitoring. N. Engl, J. Med.. 354(22), 2368-2374 (2006).
41. Wachtell K, Bella JN, Liebson PR et al.: Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population. The LIFE study. Hypertension 35, 6-12 (2000).
42. Devereux RB, Alonso DR, Lutas EM et al.: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J. Cardiol. 57, 450-458 (1986).
43. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE: Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96, 1432-1437 (1997).
44. Kanters SD, Algra A, van Leeuwen MS, Banga JD: Reproducibility of in vivo carotid intima-media thickness measurements: a review. Stroke 28(3), 665-671 (1997).
45. Sung KR, Eun YC, Hyun-Young P et al.: Renin-angiotensin-aldosterone system (RAAS) gene polymorphism as a risk factor of coronary in-stent restenosis. Yonsei Med. J. 43, 461-472 (2002).
46. Williams TA, Mulatero P, Filigheddu F et al.: Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides. Kidney Int. 67, 631-637 (2005).
47. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D: Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38(8), 904-909 (2006).
48. Hiltunen TP, Suonsyrja T, Hannila-Handelberg T et al.: Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am. J. Hypertens. 20(3), 311-318 (2007).
49. Frankel WN, Schork NJ: Who's afraid of epistasis? Nat. Genet. 14(4), 371-373 (1996).
50. Marchini J, Donnelly P, Cardon LR: Genome-wide strategies for detecting multiple loci that influence complex diseases. Nat. Genet. 37(4), 413-417 (2005).
51. Castellano M, Glorioso N, Cusi D et al.: Genetic polymorphism of the renin-angiotensin-aldosterone system and arterial hypertension in the Italian population: the GENIPER Project. J. Hypertens. 21, 1853-1860 (2003).
52. 41st World Medical Assembly: Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. Bull, Pan. Am. Health Organ. 24, 606-609 (1990).
53. Bianchi G, Staessen JA, Patrizia F: Pharmacogenornics of primary hypertension: the lessons from the past to look toward the future. Pharmacogenomics 4(3), 279-296 (2003).
54. Jeunemaitre X, Soubrier F, Kotelevtsev YV et al.: Molecular basis of human hypertension: role of angiotensinogen. Cell 71(1), 169-180 (1992).
55. Kurland L, Liljedahl U, Karisson J et al.: Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am. J. Hypertens.. 17 (1), 8-13 (2004).
56. Tiret L, Rigat B, Visvikis S et al.: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am. J. Hum. Genet. 51(1), 197-205 (1992).
57. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86(4), 1343-1346 (1990).
58. Spiering W, Kroon AA, Fuss-Lejeune MM, Daemen MJ, de Leeuw PW: Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A (1166)C polymorphism in essential hypertensives on a high sodium diet. Hypertension 36(3), 411-416 (2000).
59. Nishimura, H, Yerkes E, Hohenfellner K et al.: Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. Mol. Cell 3, 1-10 (1999).
60. Kuznetsova T, Staessen JA, Thijs L et al.: European Project On Genes in Hypertension (EPOGH) Investigators. Left ventricular mass in relation to genetic variation in angiotensin II receptors, renin system genes and sodium excretion. Circulation 110(17), 2644-2650 (2004).
61. Lim PO, Macdonald TM, Holloway C et al.: Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio. J. Clin. Endocr. Metab. 87, 4398-4402 (2002).
62. Nicod J, Bruhin D, Auer L, Vogt B, Frey FJ, Ferrari P: A biallelic gene polymorphism of CYP11B2 predicts increased aldosterone to renin ratio in selected hypertensive patients. J. Clin. Endocr. Metab. 88, 2495-2500 (2003).
63. Jiang X, Sheng HH, Lin G et al.: Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment. Chin. Med. J. (Engl) 120(9), 782-786 (2007).
64. Tripodi G, Valtorta, F, Torielli L et al.: Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. J. Clin. Invest. 97(12), 2815-2822 (1996).
65. Ferrandi M, Tripodi G, Salardi S et al.: Renal Na,K-ATPase in genetic hypertension. Hypertension 28(6), 1018-1025 (1996).
66. Glorioso N, Filigheddu F, Cusi D et al.: α-adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives. Hypertension 39(2 Pt 2), 357-362 (2002).
67. Glorioso N, Manunta F, Filigheddu F et al.: The role of α-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 34(4 Pt 1), 649-654 (1999).
68. Cusi D, Barlassina C, Azzani T et al.: Polymorphisms of α-adducin and salt sensitivity in patients with essential hypertension. Lancet. 349(9062), 1353-1357 (1997).
69. Lovati E, Ferrari P, Dick B et al.: Molecular basis of human salt sensitivity: the role of the 11-β-hydroxysteroid clehydrogenase type 2. J. Clin. Endocr. Metab. 84, 3745-3749 (1999).
70. Agarwal AK, Mune T, Monder C, White PC: Mutations in putative glycosylation sites of rat 11 β-hydroxysteroid dehydrogenase affect enzymatic activity. Biochim. Biophys. Acta 1248(1), 70-74 (1995).
71. Mason DA, Moore JD, Green SA, Liggett SB: A gain-of-function polymorphism in a G-protein coupling domain of the human β-1-adrenergic receptor. J. Biol. Chem. 274, 12670-12674 (1999).
72. Maqbool A, Hall AS, Ball SG, Balmforth AJ: Common polymorphisms of β1-adrenoceptor: identification and rapid screening assay. Lancet. 353(9156), 897 (1999).
73. Radu DA, Brown KM, Kramer LA, Liggett SB: Amino acid 49 polymorphisms of the human β1-adrenergic receptor affect agonist-promoted trafficking. J. Cardiovasc. Pharmacol. 39, 155-160 (2002).
74. Reihsaus E, Innis M, MacIntyre N, Liggett SB: Mutations in the gene encoding for the beta (2)-adrenergic receptor in normal and asthmatic subjects. Am. J. Resp. Cell Molec. Biol. 8, 334-339 (1993).
75. Heckbert SR, Hindorff LA, Edwards KL et al.: β2-adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly. Circulation. 107(15), 2021-2024 (2003).
76. Siffert W, Rosskopf D, Moritz A et al.: Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension. J. Clin. Invest. 96, 759-766 (1995).
77. Schelleman H, Stricker BH, Verschuren WM et al.: Interactions between five candidate genes and antihypertensive drug therapy on blood pressure. Pharmacogenomics J. 6(1), 22-26 (2006).
78. Turner ST, Schwartz GL, Chapman AB et al.: C825T polymorphism of the G protein β(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension. 37(2 Part 2), 739-743 (2001).
79. Rettie AE, Wienkers LC, Gonzalez FJ et al.: Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4(1), 39-42 (1994).
80. Fukuya H, Fernandez-Salguero P, Gregory W et al.: Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5(6), 389-392 (1995).
81. Haining RL, Hunter AP, Veronese ME et al.: Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch. Biochem. Biophys. 333(2), 447-458 (1996).
82. Sullivan-Klose TH, Ghanayem BI, Bell DA et al.: The role of the CYP2C9 Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6(4), 341-349 (1996).
83. Steward DJ, Haining RL, Henne KR et al.: Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7(5), 361-367 (1997).